Recently, at the 15th China Pharmaceutical Industry Development Summit Forum hosted by the Medical and Pharmaceutical Chamber of Commerce of the All China Federation of Industry and Commerce, the "2022-2023 Most Influential Chinese Pharmaceutical Industry" list was released. Among them, CGeneTech was awarded the honor of "Independent Innovation Pioneer Enterprise in the Chinese Pharmaceutical Industry".

The "Most Influential List of China's Pharmaceutical Industry" was selected by a selection group consisting of domestic first-class experts invited by the Medical and Pharmaceutical Chamber of Commerce of the All China Federation of Industry and Commerce, and in collaboration with multiple well-known domestic media. It is known as the wind vane of China's pharmaceutical development and serves as the maximum leverage and strongest voice for award-winning enterprises.

In the list, "Chinese pharmaceutical industry independent innovation pioneer enterprises" place more emphasis on the independent innovation ability of enterprises, and representatives of domestic innovative pharmaceutical enterprises such as Hengrui, Xiansheng, Zhengda Tianqing, and Baiji Shenzhou were all selected. CGeneTech stands out among numerous innovative pharmaceutical companies in China and has been awarded this honor, thanks to the company's self-developed multiple innovative drugs advancing to the clinical stage. Among them, the leading product, Cetagliptin, a new hypoglycemic drug that has been honed for ten years, is about to enter commercialization.

As a new generation of highly selective DPP-4 inhibitors independently developed by CGeneTech, Cetagliptin Phase III clinical results show unique advantages such as high selectivity, strong inhibition, low dose, and safer, and is expected to become the best hypoglycemic drug in the class. At the 2023 Peking University diabetes Forum held in May this year, Professor Ji Linong, director of the Department of Endocrinology of Peking University People's Hospital, announced the data and results of two phase III clinical trials of Cetagliptin. In his final clinical summary, he said that Cetagliptin was very effective and safe, and hoped that it could provide clinicians with better drugs for diabetes treatment as soon as possible.

With the increasing popularity of DPP-4 inhibitors in China, the market size of such drugs (all imported) will reach nearly 10 billion yuan in 2022. Combined treatment is an important mode of treatment for diabetes. Cetagliptin can be used in combination with most mainstream hypoglycemic drugs, mainly metformin and gliclazide (SGLT-2), which can not only play the advantages of hypoglycemic drugs with different mechanisms, but also not increase additional side effects. Therefore, according to the Sullivan research report, by 2030, the market size of statins in China will exceed 30 billion, and the future is foreseeable.

Dr. Yu Qiang, founder and CEO of CGeneTech, stated: "It is a great affirmation and encouragement for us to be selected as a pioneer of independent innovation in China's pharmaceutical industry. At present, the company is busy preparing for the commercialization of its core innovative product Cetagliptin. At the same time, it has launched the last round of financing before the launch of the Science and Technology Innovation Board to accelerate the construction of Cetagliptin's industrialization and commercialization. It is hoped that the drug can be launched as soon as possible to benefit the vast number of diabetes patients in China."